Advertisement
Canada markets open in 1 hour 13 minutes

  • S&P/TSX

    21,516.90
    -94.40 (-0.44%)
     

  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     

  • DOW

    38,834.86
    +56.76 (+0.15%)
     

  • CAD/USD

    0.7294
    -0.0003 (-0.05%)
     

  • CRUDE OIL

    81.57
    0.00 (0.00%)
     

  • Bitcoin CAD

    90,637.06
    +1,402.26 (+1.57%)
     

  • CMC Crypto 200

    1,374.56
    -8.10 (-0.59%)
     

  • GOLD FUTURES

    2,353.50
    +6.60 (+0.28%)
     

  • RUSSELL 2000

    2,025.23
    +3.22 (+0.16%)
     

  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     

  • NASDAQ futures

    20,022.25
    +103.00 (+0.52%)
     

  • VOLATILITY

    12.58
    +0.10 (+0.80%)
     

  • FTSE

    8,231.20
    +26.09 (+0.32%)
     

  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     

  • CAD/EUR

    0.6803
    +0.0016 (+0.24%)
     

Vigil Neuroscience to Present in Upcoming June Investor Conferences

Vigil Neuroscience, Inc.
·2 min read
Vigil Neuroscience, Inc.
Vigil Neuroscience, Inc.

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management’s participation at two upcoming investor conferences.

  • Ivana Magovčević-Liebisch, Ph.D., J.D., President & Chief Executive Officer and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6th at 9:30 a.m. E.T.

  • Ivana Magovčević-Liebisch, Ph.D., J.D., President & Chief Executive Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11th at 10:40 a.m. E.T.

The live webcasts from the events will be available on the Company’s website on the “Events & Presentations” page in the “Investors” section. Archived webcasts will be available for approximately 90 days following the presentation.

ADVERTISEMENT

About Vigil Neuroscience

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

Internet Posting of Information

Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.

Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com

Media Contact:
Megan McGrath
MacDougall Advisors
mmcgrath@macdougall.bio